Guideline for the management of clinically localized prostate cancer: 2007 update.

[1]  J. Shaeffer,et al.  Incidence of prostatic carcinoma in the elderly. , 1975, Urology.

[2]  W. Whitmore,et al.  Experience with interstitial implantation of iodine 125 in the treatment of prostatic carcinoma. , 1980, Scandinavian journal of urology and nephrology. Supplementum.

[3]  D. Gleason,et al.  Histologic Grading and Staging of Prostatic Carcinoma , 1981 .

[4]  M. Schumacher,et al.  Assessment of quality of life in clinical trials. , 1991, Statistics in medicine.

[5]  P. Walsh,et al.  Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. , 1991, Journal of Urology.

[6]  J. Blasko,et al.  Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. , 1991, Scandinavian journal of urology and nephrology. Supplementum.

[7]  T. Oei,et al.  Comparison of prostate cancer patients with and without pain , 1993, Pain.

[8]  S. Walker,et al.  Quality of Life Assessment: Key Issues in the 1990s , 1993, Springer Netherlands.

[9]  D. Osoba.  Self-rating symptom checklists: a simple method for recording and evaluating symptom control in oncology. , 1993, Cancer treatment reviews.

[10]  W. Catalona,et al.  Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. , 1993, The Journal of urology.

[11]  D. Patrick,et al.  Assessing health-related quality of life for clinical decision-making , 1993 .

[12]  J. Roy,et al.  Short-term freedom from disease progression after I-125 prostate implantation. , 1994, International journal of radiation oncology, biology, physics.

[13]  D. Grignon,et al.  High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. , 1994, In vivo.

[14]  T. Wilt,et al.  The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. , 1994, The Journal of urology.

[15]  R H Brook,et al.  Quality-of-life outcomes in men treated for localized prostate cancer. , 1995, JAMA.

[16]  D. Corle,et al.  Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. , 1995, Scandinavian journal of urology and nephrology. Supplementum.

[17]  John H. Wasson,et al.  Special Communications PROSTATE CANCER CLINICAL GUIDELINES PANEL SUMMARY REPORT ON THE MANAGEMENT OF CLINICALLY LOCALIZED PROSTATE CANCER , 1995 .

[18]  D. Cella,et al.  Measuring quality of life in palliative care. , 1995, Seminars in oncology.

[19]  J Roy,et al.  Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Srigley,et al.  Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. , 1996, The Journal of urology.

[21]  J. Forman,et al.  Patient self-assessment of complications and quality of life after conformal neutron and photon irradiation for localized prostate cancer. , 1997, Radiation oncology investigations.

[22]  I. Osterloh,et al.  The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. , 1997, Urology.

[23]  C. Begg,et al.  The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. , 1997, Urology.

[24]  S Hunt,et al.  The problem of quality of life in medicine. , 1997, JAMA.

[25]  J. Goméz,et al.  Neoadjuvant hormonal therapy: the Canadian experience. , 1997, Urology.

[26]  P. Kantoff,et al.  Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Monga,et al.  Neuromuscular fatigue in prostate cancer patients undergoing radiation therapy. , 1997, Archives of physical medicine and rehabilitation.

[28]  M. Zelefsky,et al.  Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer. , 1997, The Journal of urology.

[29]  M. Sullivan,et al.  Quality of life in patients with prostatic cancer: results from a Swedish population study. , 1997, The Journal of urology.

[30]  F. Joly,et al.  Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  A. D'Amico,et al.  5 year biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer , 1998 .

[32]  D. Lubeck,et al.  Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. , 1998, The Journal of urology.

[33]  J. Kirkpatrick.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. , 1998, Journal of insurance medicine.

[34]  P. Walsh,et al.  Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. , 1998, The Journal of urology.

[35]  D. Lubeck,et al.  Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE. , 1999, Urology.

[36]  J. W. Stallings,et al.  Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity. , 1999, International journal of radiation oncology, biology, physics.

[37]  M. Pontari,et al.  The National Institutes of Health chronic prostatitis symptom index: Development and validation of a new outcome measure , 1999 .

[38]  P. Schellhammer,et al.  Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. , 1999, Urology.

[39]  M. Litwin,et al.  Recovery of health related quality of life in the year after radical prostatectomy: early experience. , 1999, The Journal of urology.

[40]  J. Sowers,et al.  Diabetes and cardiovascular disease. , 1999, Diabetes care.

[41]  W. Catalona,et al.  Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. , 1999, The Journal of urology.

[42]  A. Zlotta,et al.  4–Year Follow–Up Results of a European Prospective Randomized Study on Neoadjuvant Hormonal Therapy prior to Radical Prostatectomy in T2–3N0M0 Prostate Cancer , 2000, European Urology.

[43]  P. Walsh,et al.  Use of intraoperative video documentation to improve sexual function after radical retropubic prostatectomy. , 2000, Urology.

[44]  J. Frankel,et al.  Use of interoperative video documentation , 2000 .

[45]  M. Kattan,et al.  Factors predicting recovery of erections after radical prostatectomy. , 2000, The Journal of urology.

[46]  R. Chou,et al.  Potency preservation after three-dimensional conformal radiotherapy for prostate cancer: preliminary results. , 2000, American journal of clinical oncology.

[47]  James A. Purdy,et al.  Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison. , 2000, International journal of radiation oncology, biology, physics.

[48]  K. Wallner,et al.  Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[49]  Caveats for modeling disease free survival after radical prostatectomy , 2000, Cancer.

[50]  R A Stephenson,et al.  Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. , 2000, JAMA.

[51]  J. Adolfsson,et al.  Localized prostate cancer and 30 years of follow-up in a population-based setting , 2000, Prostate Cancer and Prostatic Diseases.

[52]  W. Lee,et al.  A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[53]  P. Schellhammer,et al.  Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. , 2001, The Journal of urology.

[54]  G. Muto,et al.  Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study. , 2001, Urology.

[55]  G. Hanks,et al.  Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.

[56]  M. Gleave,et al.  Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. , 2001, The Journal of urology.

[57]  S. P. Mitchell,et al.  Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. , 2001, The Journal of urology.

[58]  R. Stock,et al.  Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. , 2001, International journal of radiation oncology, biology, physics.

[59]  C Coley,et al.  Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer. , 2001, Urology.

[60]  D. Grignon,et al.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.

[61]  P. Schellhammer,et al.  Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-up. , 2001, Urology.

[62]  J. Moul,et al.  The development of erectile dysfunction in men treated for prostate cancer. , 2001, The Journal of urology.

[63]  D. Lubeck,et al.  Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. , 2002, Urology.

[64]  C. Abbou,et al.  Urinary continence and erectile function: a prospective evaluation of functional results after radical laparoscopic prostatectomy. , 2002, European urology.

[65]  D. Wood,et al.  Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. , 2002, The Journal of urology.

[66]  J. Hugosson,et al.  Three‐month neoadjuvant hormonal therapy before radical prostatectomy: a 7‐year follow‐up of a randomized controlled trial , 2002, BJU international.

[67]  D. Eton,et al.  Prostate cancer and health‐related quality of life: a review of the literature , 2002, Psycho-oncology.

[68]  K. Schwartz,et al.  Complications from treatment for prostate carcinoma among men in the Detroit area , 2002, Cancer.

[69]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[70]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[71]  D. Osoba,et al.  Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials--does HRQOL evaluation in prostate cancer research inform clinical decision making? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  J. Chin,et al.  Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. , 2003, The Journal of urology.

[73]  N. Aaronson,et al.  Review Article HEALTH RELATED QUALITY OF LIFE IN MEN WITH PROSTATE CANCER , 2003 .

[74]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial , 2003 .

[75]  Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program , 2003, BJU international.

[76]  A. D'Amico,et al.  Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  J. Blasko,et al.  Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. , 2003, International journal of radiation oncology, biology, physics.

[78]  R. Fraser,et al.  Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. , 2003, International journal of radiation oncology, biology, physics.

[79]  F. Gilliland,et al.  Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study , 2003, Cancer.

[80]  J. Hugosson,et al.  Does Initial Surveillance in Early Prostate Cancer Reduce the Chance of Cure by Radical Prostatectomy?: A Case-Control Study , 2003, Scandinavian journal of urology and nephrology.

[81]  Joseph A. Smith,et al.  Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 , 2003 .

[82]  G. Lockwood,et al.  Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[83]  Warren D D'Souza,et al.  Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability. , 2004, International journal of radiation oncology, biology, physics.

[84]  F. Montorsi,et al.  Standards for clinical trials in male sexual dysfunction: erectile dysfunction and rapid ejaculation. , 2004, The journal of sexual medicine.

[85]  T. Tammela,et al.  Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. , 2004, The Journal of urology.

[86]  I. Thompson,et al.  Localized prostate cancer: quality of life meets Whitmore's legacy. , 2004, Journal of the National Cancer Institute.

[87]  D. Theodorescu,et al.  Determinants of long‐term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer , 2004, BJU international.

[88]  M. Wirth,et al.  Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. , 2004, The Journal of urology.

[89]  G. Chatta.  Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 , 2004 .

[90]  P. Ganz,et al.  Quality of life in adult survivors of lung, colon and prostate cancer , 1994, Quality of Life Research.

[91]  A. Fortin,et al.  The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. , 2004, The Journal of urology.

[92]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[93]  Y. Homma,et al.  Endocrine therapy with or without radical prostatectomy for T1b‐T3N0M0 prostate cancer , 2004, International journal of urology : official journal of the Japanese Urological Association.

[94]  Ming-Hui Chen,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2004, The New England journal of medicine.

[95]  D. Prezioso,et al.  Neoadjuvant Hormone Treatment with Leuprolide Acetate Depot 3.75 mg and Cyproterone Acetate, before Radical Prostatectomy: A Randomized Study , 2004, Urologia Internationalis.

[96]  Y. Homma,et al.  Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five‐year results , 2004, International journal of urology : official journal of the Japanese Urological Association.

[97]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[98]  W. See.  Bicalutamide adjuvant to radical prostatectomy. , 2004, Reviews in urology.

[99]  Paul W Dickman,et al.  Natural history of early, localized prostate cancer. , 2004, JAMA.

[100]  D. Kuban,et al.  Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. , 2005, The Journal of urology.

[101]  W. J. Morris,et al.  Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  Ming-Hui Chen,et al.  Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. , 2005 .

[103]  A. Hanlon,et al.  Radiation therapy as treatment for stage T1c prostate cancers , 2005, World Journal of Urology.

[104]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[105]  M. Dempster,et al.  Assessing health-related quality of life , 2005 .

[106]  M. Zelefsky.  The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity , 2005 .

[107]  Daniel W. Miller,et al.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.

[108]  小川 和彦.  What's going on 放射線 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. JAMA. 2004;292:821-7. PMID:15315996--放射線治療 , 2005 .

[109]  Early outcomes of active surveillance for localized prostate cancer , 2005 .

[110]  L. Klotz.  Active surveillance for prostate cancer: for whom? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  P. Walsh.  6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate Cancer: A Randomized Controlled Trial , 2005 .

[112]  J. Blasko,et al.  Comparison of biochemical failure definitions for permanent prostate brachytherapy. , 2005, International journal of radiation oncology, biology, physics.

[113]  E. Arias,et al.  United States life tables, 2005. , 2010, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[114]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  B. Trock,et al.  Delayed versus immediate surgical intervention and prostate cancer outcome. , 2006, Journal of the National Cancer Institute.

[116]  L. Klotz.  Active surveillance with selective delayed intervention for favorable risk prostate cancer. , 2006, Urologic oncology.

[117]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[118]  Pierre Mongiat-Artus,et al.  Prostate Cancer and the Will Rogers Phenomenon , 2006 .

[119]  M. Morrow,et al.  Five-Year Outcomes After Prostatectomy or Radiotherapy for Prostate Cancer: The Prostate Cancer Outcomes Study , 2006 .

[120]  G. Aus,et al.  Current status of HIFU and cryotherapy in prostate cancer--a review. , 2006, European urology.

[121]  R. Stock,et al.  Disease-specific survival following the brachytherapy management of prostate cancer. , 2006, International journal of radiation oncology, biology, physics.

[122]  Anthony V D'Amico,et al.  Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. , 2007, The Journal of urology.